Official ESCRS | European Society of Cataract & Refractive Surgeons
Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance

Take a look inside the London 2014 Congress


Then register to join us
in Barcelona!

Extending depth of focus for hyperopic presbyopes with laser vision correction and corneal inlay implantation

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Session Details

Session Title: Corneal and Scleral Treatment

Session Date/Time: Wednesday 09/09/2015 | 08:00-09:30

Paper Time: 08:54

Venue: Room 13

First Author: : W.Riha AUSTRIA

Co Author(s): :    J. Machat                    

Abstract Details


Evaluate the effectiveness of combining hyperopic LASIK and corneal inlay implantation to extend depth of focus for hyperopic presbyopes.


Crystal Clear Vision Canada, 33 Hazelton Avenue, Toronto, Canada


Retrospective analysis of 2022 hyperopic presbyopes treated at 16 centers in 10 countries. A small aperture corneal inlay was implanted monocularly into the non-dominant eye into a secondary lamellar pocket subsequent to bilateral laser vision correction. Manifest spherical equivalent refraction (MRSE), uncorrected (U) near (N) and distance (D) visual acuity (VA), and best-corrected (BC) DVA were evaluated pre-operatively (n = 2022), week 1 (n= 1678), month 1 (n= 1822), month 3 (n= 1688), month 6 (n= 1413), month 12 (n= 997) and month 18 (n= 502). Visual acuity is represented in Snellen.


UCDVA improved from 20/21 at preop to 20/17 at 18-months (p<0.0001). UCNVA improved 4.5 lines from 20/78 at pre-op to 20/28 at 18-months (p<0.0001). At 18 months, the MRSE in the inlay eye was -0.40 ± 0.63. 100% of patients achieved a BCDVA of >20/25 at 18 months. 0.22% experienced a sustained loss of 2 or more lines of BCDVA at 18 months. 95.8% of patients were within ±1.0D of target refraction.


Combining hyperopic laser vision correction and small aperture inlay implantation extends depth of focus by significantly improving both uncorrected near and distance visual acuity in treated eyes.

Financial Interest:

One of the authors travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented

Back to previous